Breaking Stories

Regeneron developing antibodies to target omicron as current cocktail loses potency against variant

CEO Leonard Schleifer told CNBC Regeneron plans to conduct trials on the new antibodies in the first quarter of 2022.

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *